Guidelines

• NCCN Guidelines Version 2.2022

Evidence Blocks

• NCCN Guidelines with Evidence Blocks Version 2.2022

Guidelines for Patients

• Chronic Lymphocytic Leukemia-English Version 2021

• Chronic Lymphocytic Leukemia-Arabic Version 2021

Educational Events and Programs

Calendar of Events

Continuing Education

• Updates in the Management of CLL/SLL: Management of Relapsed/Refractory Disease and the Role of Minimal Residual Disease

• Guideline Updates and Real-World Experiences in CLL: State-of-the-Art Evidence and Next Questions

• Case 1: Newly Diagnosed CLL/SLL without del(17p)/TP53 mutation in a patient <65 years without significant comorbidities

• Case 2: Newly Diagnosed CLL/SLL with del(17p)/TP53 mutation

• Case 3: Relapsed CLL/SLL without del(17p)/TP53 mutation in a patient ≥65 years

• Case 4: Relapsed CLL/SLL with del(17p)/TP53 mutation and ibrutinib intolerance in a patient ≥65 years

• Optimizing Treatment Approaches for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

• Minimal Residual Disease Assessment in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Is it Ready for Routine Clinical Practice?

• Applying Guideline Updates and Real-World Experience in CLL: Experts Review State-of-the-Art Evidence and Address Clinical Challenges

International

Disclosures

• Disclosure Policy

• Panel Member Disclosures

• Panel Member Disclosures by Meeting Date

• End User License Agreement